Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms EXCHANGE
- Sponsors Novartis Pharmaceuticals
- 27 Mar 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned End Date changed from 14 Jan 2020 to 27 Apr 2020.
- 31 Jan 2019 Planned initiation date changed from 17 Sep 2018 to 31 Jan 2019.